+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 56 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of B001 injection in patients who have neuromyelitis optica spectrum disorder NMOSD and test positive for aquaporin-4 antibodies. This condition involves recurrent attacks affecting the nervous system. The study is a multicenter, randomized, double-blind, placebo-controlled trial conducted in phases II and III to understand how well B001 works and how safe it is for these patients. Participants will receive intravenous doses of either B001 or a placebo on Day 1 and Day 15 during the randomized controlled period. The study includes two groups one receiving B001 injections and the other receiving placebo injections matching B001s schedule. The trial will extend over several years, monitoring patients closely for disease relapse and treatment side effects. During the study, participants will be regularly assessed for the time to their first NMOSD attack, changes in disability status, vision acuity, and opticospinal function. Researchers will also observe the annual relapse rate and document any adverse events. The trial includes safety monitoring for about three years to ensure comprehensive data collection on treatment impact and participant health.

Age: 18Years +All GendersPhase 2Phase 3
51 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of TQB2102 for injection compared to a standard drug regimen in the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer. This phase III randomized, open-label, multi-center trial involves about 544 patients who will be assigned to receive either TQB2102 or a combination of Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin. The study aims to assess key outcomes such as total physiological complete response tpCR, breast pathological complete response bpCR, objective response rate ORR, event-free survival EFS, invasive disease-free survival IDFS, overall survival OS, and safety indicators including adverse events and immune response markers. Participants in the TQB2102 group will receive 8 cycles of intravenous infusion every 3 weeks, each cycle lasting 21 days. The comparator group will receive 6 cycles of a combination treatment with Trastuzumab, Pertuzumab, Docetaxel, and Carboplatin, also administered intravenously every 3 weeks for 21-day cycles. After completing the assigned treatment cycles, all participants will undergo breast cancer surgery. Following surgery, there will be visits to monitor disease recurrence and overall survival. Throughout the study, participants will be closely monitored with evaluations conducted up to 50 months after study start. These include assessments of tumor response by independent review and investigators, safety monitoring from consent through 40 days post last dosing or surgery, and testing for anti-drug and neutralizing antibodies. Participants will have scheduled visits for treatment administration, surgery, and follow-up to track outcomes and safety over several years.

Age: 18Years - 75YearsAll GendersPhase 3
77 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.

Age: 18Years +All GendersPhase 3
210 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TQ05105 Tablets combined with TQB3617 Capsules in people with intermediate- and high-risk Myelofibrosis, a type of bone marrow cancer. This open, single-arm, multi-center clinical trial is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and aims to find the best dose and measure improvements in spleen size and symptoms over time. Participants will take TQ05105 Tablets, which target Janus kinase 1 and 2 enzymes, together with TQB3617 Capsules, which inhibit bromodomain and extra-terminal proteins. Both medications are taken orally in 21-day treatment cycles. The study includes an initial phase to determine the maximum tolerated dose and recommended dose, followed by longer evaluation periods lasting up to 120 weeks. During the study, participants will undergo regular assessments including measurement of spleen volume, symptom questionnaires, gene mutation analysis, and monitoring of side effects. The main outcomes focus on spleen volume reduction and symptom improvement, as well as survival and safety over the study period. Total participation may last up to two years, with ongoing monitoring to evaluate treatment response and tolerability.

Age: 18Years +All GendersPhase 1Phase 2
22 locations
R

Actively Recruiting

This research aims to evaluate the effects of TQH3906 Capsules in adults with active Psoriatic Arthritis PsA. The study plans to enroll 156 participants to assess how different doses of TQH3906 compare to placebo in improving PsA symptoms at Week 12, focusing on the proportion of participants reaching a 20% improvement according to the American College of Rheumatology criteria. Participants will be randomly assigned to receive one of several oral treatments daily from Day 1 to Day 169. These include 24 mg or 16 mg doses of TQH3906 capsules, a placebo phase followed by TQH3906, or an active comparator, Tofacitinib Citrate tablets. The study uses a double-blind design to compare these treatments effects and safety. Throughout the study, participants will attend visits for assessments including the ACR improvement criteria at multiple time points up to Day 169. Blood samples will be collected to evaluate drug levels and immune markers, and safety will be monitored closely. The main outcome is the proportion of participants achieving ACR20 response at Week 12. The study duration extends up to November 2027, with detailed evaluations of drug effects and adverse events throughout.

Age: 18Years - 70YearsAll GendersPhase 2
44 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of TQB6411 for injection in adults with advanced lung cancer. This phase IbII clinical trial aims to find the recommended phase II dosage and assess how well the treatment works in shrinking tumors or controlling the disease. The study is sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and focuses on patients aged 18 to 75 years with confirmed lung cancer. Participants will receive TQB6411 injections either every 21 days or every 28 days as treatment cycles. The study involves only one treatment group where all participants receive TQB6411. Each cycle of treatment is followed by assessments to monitor response and safety. The trial includes dose evaluation and efficacy measurement over several months, with extended follow-up for survival and side effects lasting up to three years. During the study, participants will undergo medical evaluations including laboratory tests, imaging scans to measure tumors, and monitoring of adverse events. Blood samples will be taken to study drug levels and antibodies. The main outcomes measured include tumor response rates, disease control, duration of response, progression-free and overall survival. Safety is closely monitored throughout the study. The total participation time may last up to three years, including treatment and follow-up visits.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
38 locations
P

Actively Recruiting

This trial investigates TQ05105 tablets in adults with intermediate or high-risk myelofibrosis, a type of bone marrow cancer. It includes two groups one studying how the drug behaves in the body in participants with different levels of kidney function, and another assessing the drugs safety and effect in those who have not responded well or cannot tolerate previous Janus kinase JAK inhibitor treatments. The study is a phase II, open-label, single-arm, multicenter trial. Participants receive TQ05105 tablets in 28-day treatment cycles. The first group focuses on pharmacokinetics to guide dosing for normal to moderate kidney impairment. The second group evaluates the drugs safety and potential benefits in participants with spleen enlargement and prior JAK inhibitor therapy that was ineffective or intolerable. Treatment continues with regular dosing and monitoring. During the study, participants undergo assessments including measurements of spleen volume reduction and various pharmacokinetic parameters such as drug concentration over time. Safety is monitored through recording adverse events during treatment and up to 4 weeks after the last dose. Additional outcomes include symptom assessments, survival rates, and blood transfusion needs. The study lasts up to several years, with primary measurements at 24 weeks and extended follow-up averaging three years.

Age: 18Years +All GendersPhase 2
24 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and maximum tolerated dose of BPI-371153, a PD-L1 inhibitor, in patients with advanced solid tumors or relapsedrefractory lymphoma. This phase 1 open-label study aims to establish the recommended dose for further research and to understand how the drug behaves in the body and its anti-tumor activity. Participants will receive oral capsules of BPI-371153 once daily in 21-day treatment cycles. The study includes a dose escalation phase to find the maximum tolerated dose and a dose expansion phase where patients receive the recommended dose. Different patient groups include those with advanced non-small cell lung cancer, relapsed or refractory lymphoma, hepatocellular carcinoma, and other advanced solid tumors. During the study, participants will be monitored for adverse events, drug levels in the body, and tumor response over approximately 24 months. Researchers will assess tumor lesions using recognized criteria and evaluate PD-L1 expression levels. The study requires adequate organ function and performance status, with ongoing evaluation to ensure safety and determine the best dose for future studies.

Age: 18Years +All GendersPhase 1
4 locations
P

Actively Recruiting

Researchers are evaluating the appropriate dose and the safety, tolerability, and effectiveness of HLX43 combined with Serplulimab in patients with advanced lung cancer. This phase II randomized, open-label study focuses on patients with advanced non-small cell lung cancer NSCLC without actionable gene alterations and small cell lung cancer SCLC who have previously received immunotherapy and platinum-based chemotherapy. The aim is to better understand how these treatments work together in this patient group. Participants are randomly assigned to receive one of two doses of HLX43, an anti-PD-L1 antibody linked to a potent DNA topoisomerase I inhibitor, along with a fixed dose of Serplulimab, an anti-PD-1 antibody. Both medications are given by intravenous infusion every three weeks. Those who tolerate the treatment well and have controlled disease will continue receiving the combination every three weeks until disease progression, new anti-cancer therapy is started, intolerable side effects occur, death, or withdrawal of consent. During the study, participants will have regular assessments including tumor measurements according to RECIST 1.1 criteria, laboratory tests, and safety monitoring for adverse events. The main outcome measured is the overall response rate within 24 weeks, with additional measurements including progression-free survival up to 12 months and overall survival up to approximately 18 months. Follow-up for safety will continue up to 90 days after the last dose. The total duration of participation varies based on treatment response and tolerability.

Age: 18Years - 75YearsAll GendersPhase 2
10 locations
P

Actively Recruiting

Researchers are studying the safety, tolerability, and effectiveness of elecoglipron alone or combined with dapagliflozin compared to placebo in adults with type 2 diabetes mellitus T2DM who are not well controlled with lifestyle changes or other glucose-lowering medications. This Phase III trial aims to better understand how these treatments impact blood sugar control and other health measures. Participants will be randomly assigned to one of four groups elecoglipron at dose level 1 with dapagliflozin placebo, elecoglipron at dose level 2 with dapagliflozin placebo, elecoglipron at one of the studied doses combined with dapagliflozin, or matching placebos for both drugs. All medications are taken orally once daily. The study lasts 40 weeks, during which participants receive their assigned treatment and are monitored. During the study, participants will undergo regular assessments including measurements of blood sugar control HbA1c, body weight, and blood pressure from baseline to Week 40. Researchers will also track the achievement of specific blood sugar targets, weight loss percentages, and the time before needing additional diabetes medication. Safety and tolerability will be monitored throughout the treatment period. The total participation duration is approximately 40 weeks.

Age: 18Years +All GendersPhase 3
149 locations

1-10 of 56

1